Press release
Squamous Cell Carcinoma Drugs Pipeline 2024 | Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna
Explore our latest breakthroughs in Squamous Cell Carcinoma Research. Learn more about our innovative pipeline today! @ Squamous Cell Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Squamous Cell Carcinoma Pipeline Report
* August 2024:- H. Lee Moffitt Cancer Center and Research Institute- Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma. The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.
* DelveInsight's Squamous Cell Carcinoma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Squamous Cell Carcinoma treatment.
* The leading Squamous Cell Carcinoma Companies such as Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus , and others.
* Promising Squamous Cell Carcinoma Therapies such as SI-B001, IFX-1, Afatinib 40 MG, Pembrolizumab Injection, MK-3475A, and others.
Stay informed about the cutting-edge advancements in Squamous Cell Carcinoma Treatments. Download for updates and be a part of the revolution in cancer care @ Squamous Cell Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Squamous Cell Carcinoma Emerging Drugs Profile
* NBTXR-3: Nanobiotix
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with squamous cell carcinoma.
* mRNA-4157: Moderna Therapeutics
mRNA-4157 is an investigational personalized mRNA cancer vaccine, Merck's anti-PD-1 therapy, for the adjuvant treatment of patients with squamous cell carcinoma. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of patients with squamous cell carcinoma.
* HB-200: Hookipa Pharma
HB-200 is HOOKIPA's lead oncology candidate engineered with the company's proprietary replicating arenaviral vector platform. HB-200 is an alternating 2-vector immunotherapy designed to focus the immune response against the encoded antigen. It comprises two single-vector compounds with arenaviral backbones based on LCMV and PICV. Both encode and express an identical E7E6 fusion protein, comprising well characterized tumor-specific antigens for HPV16+ cancers. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with squamous cell carcinoma.
* MCLA-158: Merus
MCLA-158 (also known as Petosemtamab) is a Biclonics low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). The drug is designed to exhibit three independent mechanisms of action including inhibition of EGFR-dependent signaling, LGR5 binding leading to EGFR internalization and degradation in cancer cells, and enhanced antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis activity. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with squamous cell carcinoma.
* HFB-301001: HiFiBiO
HFB301001 is a novel fully human IgG1 class OX-40 agonistic antibody with an optimized pharmacological profile. In contrast to other anti-OX-40 antibodies, the agonistic activity of HFB301001 is further enhanced in the presence of the endogenous ligand OX-40L and does not result in reduced expression of OX-40 on T cells. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with squamous cell carcinoma.
Learn more about Squamous Cell Carcinoma Drugs opportunities in our groundbreaking Squamous Cell Carcinoma Research and development projects @ Squamous Cell Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Squamous Cell Carcinoma Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Discover the latest advancements in Squamous Cell Carcinoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Squamous Cell Carcinoma Companies and Therapies
* Sichuan Baili Pharmaceutical Co., Ltd.: SI-B001
* InflaRx GmbH: IFX-1
* Merck Sharp & Dohme LLC: MK-3475A
* ImmunityBio Inc.- Aldoxorubicin HCl
* Incyte Corporation: INCB099280
Scope of the Squamous Cell Carcinoma Pipeline Report
* Coverage- Global
* Squamous Cell Carcinoma Companies- Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, and others.
* Squamous Cell Carcinoma Therapies- SI-B001, IFX-1, Afatinib 40 MG, Pembrolizumab Injection, MK-3475A , and others.
* Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Squamous Cell Carcinoma Pipeline on our website @ Squamous Cell Carcinoma Drugs and Companies [https://www.delveinsight.com/sample-request/squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Squamous Cell Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Squamous Cell Carcinoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* NBTXR-3: Nanobiotix
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* HB-200: Hookipa Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* HFB-301001: HiFiBiO
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Squamous Cell Carcinoma Key Companies
* Squamous Cell Carcinoma Key Products
* Squamous Cell Carcinoma- Unmet Needs
* Squamous Cell Carcinoma- Market Drivers and Barriers
* Squamous Cell Carcinoma- Future Perspectives and Conclusion
* Squamous Cell Carcinoma Analyst Views
* Squamous Cell Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=squamous-cell-carcinoma-drugs-pipeline-2024-hookipa-pharma-zenith-epigenetics-hifibio-nanobiotix-gsk-astrazeneca-vcn-biosciences-moderna]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Squamous Cell Carcinoma Drugs Pipeline 2024 | Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna here
News-ID: 3616510 • Views: …
More Releases from ABNewswire
Little Master Malaysia Opens First Flagship in Singapore: A New Era of Trilingua …
Singapore - 1 September, 2025 - Pioneering Malaysian children's enrichment brand Award-Winning Little Master is set to launch its first international flagship centre in Singapore this August 2025. Known for its customised trilingual learning approach (Mandarin, English, Malay) and 1-on-1 customised lessons, Little Master's expansion marks a major step in shaping how young children acquire languages in multicultural environments according to their comfort and pace.
The 100th outlet sees First Flagship…
SERVPRO of Ocala Celebrates 50 Years of Service to Marion County
Ocala, FL - SERVPRO of Ocala & South Marion County is proud to announce its 50th anniversary, marking five decades of trusted service in disaster restoration, cleanup, and construction for the Ocala community.
Founded in 1974 by Roger and Dottie Williams, SERVPRO of Ocala began as a small carpet cleaning business and has grown into a full-service restoration and recovery company. Today, under the leadership of second-generation owner Gregory T. Williams,…
New York Medical License Defense Attorney Jason Bassett Protects Healthcare Care …
New York medical license defense attorney Jason Bassett (https://jbassettlaw.com/practice-items/medical-professionals/) of the Law Offices of Jason Bassett, P.C. offers legal representation in the high-stakes area of medical license defense law. Allegations of professional misconduct against doctors, nurses, and other licensed providers can lead to license suspension, permanent revocation, and lasting damage to professional reputations. Legal support from Jason Bassett is available to medical professionals across Long Island at risk of disciplinary…
Best in ATX 2025 Award Winners Announced
Celebrating the top businesses shaping Austin's culture and community
Image: https://dashboard.kingnewswire.com/uploads/press-release/2025/09/01/175671974368b56a7fd9656175671974368b56a7fd9657.jpeg
Austin, Texas - September 1, 2025 - Best in ATX [http://bestinatx.com/] today announced the 2025 Award Winners, honoring standout businesses that embody the creativity, culture, and community spirit of Austin. This annual recognition highlights leaders that set the standard for excellence in their industries.
"This year's winners represent the very best of Austin,from established icons to innovative newcomers," said Jordan McAllister, Communications…
More Releases for Squamous
Forecasting the Future: Advanced Non-Squamous and Squamous NSCLC Market 2032 and …
The latest competent intelligence report published by CoherentMI with the title "An Increase in Demand and Opportunities for Global Advanced Non-Squamous and Squamous NSCLC Market 2025" provides a sorted image of the Advanced Non-Squamous and Squamous NSCLC industry by analysis of research and information collected from various sources that have the ability to help the decision-makers in the worldwide market to play a significant role in making a gradual impact…
Squamous Cell Carcinoma Pipeline Insights Report | DelveInsight
DelveInsight's, "Squamous Cell Carcinoma Pipeline Insight" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Squamous Cell Carcinoma pipeline landscape. It covers the Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Squamous Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights…
Advanced Non-Squamous and Squamous NSCLC Market Size, Share, Emerging Trends, Fo …
According to a new report published by CoherentMI The advanced non-squamous and squamous NSCLC market is estimated to be valued at USD 10.89 Bn in 2024 and is expected to reach USD 16.58 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7% from 2024 to 2031.
Most recent Report, named "Advanced Non-Squamous and Squamous NSCLC Market" Patterns, Offer, Size, Development, Opportunity and Forecast 2024-2031, by CoherentMI…
Best Statistical Advanced Non-Squamous and Squamous NSCLC Market Growth Set to S …
The latest competent intelligence report published by CoherentMI with the title "An Increase in Demand and Opportunities for Global Advanced Non-Squamous and Squamous NSCLC Market 2024" provides a sorted image of the Advanced Non-Squamous and Squamous NSCLC industry by analysis of research and information collected from various sources that have the ability to help the decision-makers in the worldwide market to play a significant role in making a gradual impact…
Squamous Cell Carcinoma Treatment Drugs, Pipeline Insights Report 2024
DelveInsight's, "Squamous Cell Carcinoma Pipeline Insight, 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Squamous Cell Carcinoma pipeline landscape. It covers the Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Squamous Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
Squamous Cell Carcinoma Pipeline Drugs, FDA Approvals, and Companies 2024
DelveInsight's, "Squamous Cell Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Squamous Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Pancreatic Ductal Adenocarcinoma Research.…
